Top Suppliers:I want be here

No recommended suppliers. I want be here

Hot CAS#:
56-41-7 108-65-6
56-35-9 64-17-5
67-56-1 108-88-3
141-78-6 1310-73-2
13463-67-7 1333-86-4

163133-43-5

163133-43-5 structure
163133-43-5 structure
  • Name: naproxcinod
  • Chemical Name: naproxcinod
  • CAS Number: 163133-43-5
  • Molecular Formula: C18H21NO6
  • Molecular Weight: 347.36200
  • Catalog: Research Areas Inflammation/Immunology
  • Create Date: 2018-08-05 19:14:22
  • Modify Date: 2024-01-09 22:58:43
  • Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].
Name naproxcinod
Synonyms Naproxcinod
2-(S)-(6-methoxy-2-naphthyl)-propanoic acid 4-nitroxybutyl ester
HCT-3012
2-(S)-(6-methoxy-2-naphthyl)-propanoic acid nitrooxybutyl ester
4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
Nitronaproxen
2-(S)-(6-methoxy-2-naphthyl)propanoic acid 4-(nitrooxy)butyl ester
AZD-3582
(S)-2-(6-methoxy-2-naphthyl)propionic acid 4-nitrooxybutyl ester
naproxen-n-butyl nitrate
Description Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].
Related Catalog
In Vitro Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2]. Western Blot Analysis[2] Cell Line: Endothelial and gastric mucosal cell lines Concentration: 30-1000 μM Incubation Time: 8 and 24 hours Result: Increased HO-1 protein levels in endothelial and gastric mucosal cells and increased HO-1mRNA levels in endothelial cells.
In Vivo Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD[3]. Animal Model: C57BL/10 mice with Duchenne muscular dystrophy (DMD)[3] Dosage: 0, 10, 21 and 41 mg/kg Administration: Oral gavage; 0-41 mg/kg once daily for 42 weeks Result: Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
References

[1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5.

[2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35.

[3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49.
Density 1.213
Boiling Point 489.475ºC at 760 mmHg
Molecular Formula C18H21NO6
Molecular Weight 347.36200
Flash Point 193.208ºC
Exact Mass 347.13700
PSA 90.58000
LogP 4.00680

Chemsrc provides CAS#:163133-43-5 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 163133-43-5 | Chemsrc address: https://www.chemsrc.com/en/baike/248023.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved